Q4 2025 Management View CEO Robert Ford highlighted that 2025 showcased "Abbott's leadership in innovation, disciplined execution and strategic actions taken to position the company for sustainable ...

Abbott Laboratories (NYSE:ABT) detailed fourth-quarter 2025 results and outlined its 2026 outlook on its earnings conference call, emphasizing continued momentum in medical devices, a transition plan ...

Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the company’s shares.

Abbott’s stock has fallen by over 7% despite reporting strong fiscal year 2025 (FY25) revenues of $44.32bn, representing a ...

Abbott reports fourth-quarter sales that miss analysts’ estimates.

The Dark Energy Survey Collaboration collected information on hundreds of millions of galaxies across the universe using the ...